Tau imaging detects distinctive distribution of tau pathology in ALS/PDC on the Kii Peninsula
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received May 15, 2018
- Accepted in final form September 10, 2018
- First Published December 7, 2018.
Article Versions
- Previous version (December 7, 2018 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Hitoshi Shinotoh, MD, PhD,
- Hitoshi Shimada, MD, PhD,
- Yasumasa Kokubo, MD, PhD,
- Kenji Tagai, MD,
- Fumitoshi Niwa, MD, PhD,
- Soichiro Kitamura, MD, PhD,
- Hironobu Endo, MD, PhD,
- Maiko Ono, PhD,
- Yasuyuki Kimura, MD, PhD,
- Shigeki Hirano, MD, PhD,
- Maya Mimuro, MD, PhD,
- Masanori Ichise, MD, PhD,
- Naruhiko Sahara, PhD,
- Ming-Rong Zhang, PhD,
- Tetsuya Suhara, MD, PhD and
- Makoto Higuchi, MD, PhD
- Hitoshi Shinotoh, MD, PhD,
NONE
NONE
NONE
Neurology, editorial board, 2017-2018.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hitoshi Shimada, MD, PhD,
NONE
NONE
NONE
NONE
I hold a patent on tau imaging agents (JP 5422782/EP 12 884 742.3).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
The young scientists (A) (26713031) and Grant-in-Aid for Scientific Research (C) (18K07543) from the Ministry of Education, Culture, Sports, Science and Technology, Japan.
NONE
Grants from the Mochida Memorial Foundation for Medical Pharmaceutical Research, the Life Science Foundation of Japan, the Kashiwado Memorial Foundation, and the Japan Foundation for Aging and Health
NONE
NONE
I received royalty payment from APRINOIA Therapeutics Inc. in accordance with a license agreement between APRINOIA and my institution on the patent claiming inventions of tau imaging agents (JP 5422782/EP 12 884 742.3).
NONE
NONE
NONE
- Yasumasa Kokubo, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) the Research Committee of CNS Degenerative Diseases, Ministry of Health, Labor and Welfare (MHLW), Japan, H26-Nanchi- Ippan-085, collaborator, 2014 - 2016 (2) the Research Committee of Muro disease (Kii ALS/PDC), Ministry of Health, Labor and Welfare (MHLW), Japan, 21210301, Chair, 2009-2014 (3) the Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), 25305030, Chair, 2013 - 2017 (4) the Japan Agency for Medical Research and Development, AMED, 16ek0109139h002, Chair, 2015 - 2017
(1) the Mie Medical Fund, Japan (2) Japan Foundation for Neuroscience and Mental Health
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kenji Tagai, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Fumitoshi Niwa, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Kyoto Prefectural University of Medicine
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Soichiro Kitamura, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hironobu Endo, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Maiko Ono, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Yasuyuki Kimura, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) JSPS KAKENHI, JP18964417, P.I., 3 years, (2) JSPS KAKENHI, JP18973166, co-Investigator, 3 years, (3) JSPS KAKENHI, JP17913575, P.I., 3 years, (4) JSPS KAKENHI, JP15593412, , P.I., 3 years, (5) AMED, JP17lm0203007, co- Investigator, 3 years, (6) NCGG Research Funding for Longevity Sciences, 29- 29, P.I., 3 years
Visiting lecturer, Department of Radiology, Fujita Health University
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Shigeki Hirano, MD, PhD,
NONE
NONE
(1)Nihon medi-phisics Co., Ltd., honoraria.
Journal of Alzheimer's Diease, 2018.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)Nihon Medi-Physics Co., Ltd. (2)Ely-Lilly Japan
KAKENHI (Grant-in-aid for scientific research)26461307, 17K09793
NONE
(1)The Mazda Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Maya Mimuro, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Masanori Ichise, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Naruhiko Sahara, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) The ministry of education, culture, sports, science and technology, Japan, 26117001, principle investigator, 5 years, (2) The ministry of education, culture, sports, science and technology, Japan, 15K06793, principle investigator, 3 years, (3) Japan agency for medical research and development, JP18dm0107062, co-investigator, 5 years.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ming-Rong Zhang, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tetsuya Suhara, MD, PhD and
NONE
NONE
NONE
International journal of Neuropsychopharmacology, editorial board 2004-
I hold a patent on tau imaging agents (JP 5422782/EP 12 884 742.3).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
AMED Grant Number JP H27 JP15dm0207007,H28 JP16dm0207007,H29 JP17dm0207007,H30 JP18dm0207007 (2015- 2018),H28 JP16dm0107094,H29 JP17dm0107094, H30 JP18dm0107094 (2016-2018).
NONE
NONE
NONE
My institute made a license agreement with APRINOIA Therapeutica, Inc. on the patent claiming investigation of tau imaging agent(JP 5422782/EP 12 884 742.3).
I received royalty payment from APRINOIA Therapeutics. Inc. in accordance with a license agreement between APRINOIA and my institute on the payment claiming inventions of tau imaging agents (JP 5422782/EP 12 884 742.3).
NONE
NONE
NONE
- Makoto Higuchi, MD, PhD
NONE
NONE
NONE
NONE
I hold a patent on tau imaging agents (JP 5422782/EP 12 884 742.3).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Grants-in-aid for the Brain Mapping by Integrated Neurotechnologies for Disease Studies (Brain/MINDS; 15653129)from the Japan Agency for Medical Research and Development (AMED) Research and Development Grants for Dementia (16768966) from AMED Grants for Scientific Research on Innovative Areas (?Brain Environment? 23111009) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan
NONE
NONE
NONE
My institution made a license agreement with APRINOIA Therapeutics, Inc. on the patent claiming inventions of tau imaging agents (JP 5422782/EP 12 884 742.3).
I received royalty payments from APRINOIA Therapeutics, Inc. in accordance with a license agreement between APRINOIA and my institution on the patent claiming inventions of tau imaging agents (JP 5422782/EP 12 884 742.3).
NONE
NONE
NONE
- From the Departments of Functional Brain Imaging Research (H. Shinotoh, H. Shimada, K.T., S.K., M.O., Y. Kimura, S.H., M.I., N.S., T.S., M.H.) and Radiopharmaceuticals Development (M.-R.Z.), National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba; Neurology Clinic Chiba (H. Shinotoh); Kii ALS/PDC Research Center (Y. Kokubo), Mie University; Department of Neurology and Gerontology (F.N.), Graduate School of Medical Science, Kyoto Prefectural University of Medicine; Department of Psychiatry (S.K.), Nara Medical University; Division of Neurology (H.E.), Kobe University Graduate School of Medicine, Hyogo; Center for Development of Advanced Medicine for Dementia, Department of Neurology (Y. Kimura), National Institute for Geriatrics and Gerontology, Aichi; Department of Neurology (S.H.), Chiba University; and Department of Neuropathology (M.M.), Institute for Medical Science of Aging, Aichi Medical University, Japan.
- Correspondence
Dr. Shinotoh hitoshi.shinoto{at}nifty.com or Dr. Kokubo ktyktykty{at}me.com
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.